Erasca Narrows Q3 Loss, R&D Spend Declines Amid Cash Burn

Ticker: ERAS · Form: 10-Q · Filed: Nov 12, 2025 · CIK: 1761918

Sentiment: mixed

Topics: Biotechnology, Oncology, Clinical-Stage, Cash Burn, Net Loss, R&D Expenses, RAS/MAPK Pathway

Related Tickers: ERAS

TL;DR

**Erasca is burning cash, but slowing the bleed; still, they need more money to keep their cancer pipeline alive.**

AI Summary

Erasca, Inc. reported a net loss of $30.6 million for the three months ended September 30, 2025, a slight improvement from the $31.2 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss significantly decreased to $95.5 million from $129.4 million in 2024. Research and development expenses decreased by 22% to $69.6 million for the nine months ended September 30, 2025, compared to $89.2 million in the prior year, reflecting a reduction in in-process R&D expenses from $22.5 million to $9.5 million. General and administrative expenses also saw a decline to $29.2 million from $32.1 million. The company's cash, cash equivalents, and marketable securities stood at $362.4 million as of September 30, 2025, down from $423.5 million at December 31, 2024. Erasca believes its current cash position will fund operations for at least one year, but acknowledges the need for future financing to support its clinical-stage precision oncology pipeline, which focuses on RAS/MAPK pathway-driven cancers.

Why It Matters

For investors, Erasca's reduced net loss and R&D expenses signal a potential shift towards more disciplined spending, which is crucial for a clinical-stage biotech with no product revenue. However, the continued significant cash burn and reliance on future financing pose a substantial risk, especially in a competitive oncology market where drug development is lengthy and expensive. Employees face job security concerns if financing efforts falter, while customers (future patients) depend on the company's ability to sustain development of its RAS/MAPK pathway-driven cancer therapies. The broader market watches Erasca as an indicator of investor appetite for early-stage oncology plays and the challenges of bringing innovative treatments to market.

Risk Assessment

Risk Level: high — Erasca, Inc. has an accumulated deficit of $863.1 million as of September 30, 2025, and has incurred significant operating losses and negative cash flows from operations since inception. While the company believes its $362.4 million in cash, cash equivalents, and marketable securities will fund operations for at least one year, it explicitly states it does not expect product sales revenue for several years and will need additional financing, which may not be available on favorable terms or at all.

Analyst Insight

Investors should monitor Erasca's cash burn rate closely and look for concrete updates on financing efforts or significant clinical trial milestones. Given the high risk and reliance on future capital, a cautious approach is warranted; consider this a speculative investment until a clear path to sustainable funding or late-stage clinical success emerges.

Financial Highlights

debt To Equity
0.21
revenue
N/A
operating Margin
N/A
total Assets
$420.4M
total Debt
$72.5M
net Income
-$30.6M
eps
-$0.11
gross Margin
N/A
cash Position
$362.4M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Erasca, Inc.'s primary focus as a company?

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. This includes targeting upstream and downstream signaling nodes, RAS directly, and escape routes.

How much cash and marketable securities did Erasca, Inc. have as of September 30, 2025?

As of September 30, 2025, Erasca, Inc. had $362.4 million in cash, cash equivalents, and marketable securities. This is a decrease from $423.5 million at December 31, 2024.

What was Erasca, Inc.'s net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Erasca, Inc. reported a net loss of $95.454 million. This represents a significant improvement compared to the $129.418 million net loss reported for the same period in 2024.

How have Erasca, Inc.'s research and development expenses changed?

Research and development expenses for Erasca, Inc. decreased to $69.613 million for the nine months ended September 30, 2025, from $89.237 million in the prior year. This 22% reduction was partly due to lower in-process R&D expenses.

Does Erasca, Inc. expect to generate revenue from product sales soon?

No, Erasca, Inc. does not expect to generate any revenues from product sales unless and until it successfully completes development and obtains regulatory approval for any of its product candidates, which it states will not be for at least the next several years, if ever.

What is Erasca, Inc.'s accumulated deficit?

As of September 30, 2025, Erasca, Inc. had an accumulated deficit of $863.1 million. This reflects the significant operating losses incurred since the company's inception.

What is the company's outlook on its cash runway?

Erasca, Inc. believes its cash, cash equivalents, and marketable securities as of September 30, 2025, will be sufficient to fund operations for at least one year from the issuance date of these condensed consolidated financial statements.

What are the main risks to Erasca, Inc.'s financial condition?

The main risks include the company's significant operating losses, negative cash flows, and the need to secure additional financing through equity offerings, debt financings, or collaborations. Failure to raise capital could force delays, reductions, or termination of research and development programs.

How many shares of common stock did Erasca, Inc. have outstanding?

As of November 5, 2025, Erasca, Inc. had 283,711,805 shares of common stock outstanding. This is an increase from 283,218,344 shares outstanding at December 31, 2024.

What was the change in total assets for Erasca, Inc. from December 31, 2024, to September 30, 2025?

Erasca, Inc.'s total assets decreased from $502.526 million as of December 31, 2024, to $420.401 million as of September 30, 2025. This represents a reduction of $82.125 million.

Risk Factors

Industry Context

Erasca operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on precision oncology. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Companies like Erasca aim to develop targeted therapies for specific genetic mutations, such as those in the RAS/MAPK pathway, which are prevalent in various cancers. Success hinges on innovative science, successful clinical trials, and navigating complex regulatory landscapes.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Erasca is subject to stringent regulations by bodies like the FDA. The development and approval process for its oncology pipeline candidates are critical. Any delays, setbacks in clinical trials, or failure to meet regulatory standards could significantly impact the company's ability to bring its therapies to market and achieve commercial success.

What Investors Should Do

  1. Monitor R&D Pipeline Progress
  2. Assess Future Financing Needs
  3. Evaluate Competitive Landscape
  4. Analyze Cash Runway and Burn Rate

Key Dates

Glossary

Accumulated Deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total historical losses that have not been offset by profits. (Indicates Erasca's history of operating losses, with a significant accumulated deficit of $863.1 million as of September 30, 2025.)
In-process research and development (IPR&D)
Costs incurred for research and development projects that have not yet reached technological feasibility or have no alternative future use. These are often expensed immediately. (A significant decrease in IPR&D expenses from $22.5 million in 9M 2024 to $9.5 million in 9M 2025 contributed to the overall reduction in R&D spending.)
Marketable Securities
Investments in debt or equity securities that are readily traded on public exchanges and can be quickly converted to cash. (A substantial portion of Erasca's liquid assets are held in marketable securities, totaling $292.15 million ($218.17M short-term + $73.98M long-term) as of September 30, 2025.)
RAS/MAPK pathway
A critical signaling pathway in cells that regulates cell growth, proliferation, and survival. Mutations in this pathway are common in many types of cancer. (Erasca's precision oncology pipeline focuses on targeting cancers driven by mutations in this pathway, highlighting a specific area of therapeutic focus.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Erasca has demonstrated improved financial performance by significantly reducing its net loss from $129.4 million to $95.5 million. This reduction was driven by a substantial decrease in R&D expenses, down 22% to $69.6 million, notably due to lower in-process R&D costs. General and administrative expenses also saw a decline. However, the company's cash and marketable securities position has decreased from $423.5 million at the end of 2024 to $362.4 million as of September 30, 2025, highlighting an increased reliance on its current cash runway.

Filing Stats: 4,408 words · 18 min read · ~15 pages · Grade level 19 · Accepted 2025-11-12 16:16:36

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 38 Item 4. Mine Safety Disclosures 38 Item 5. Other Information 38 Item 6. Exhibits 39

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

. Financial Statements

Item 1 . Financial Statements. Erasca, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and par value amounts) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 70,230 $ 67,739 Short-term marketable securities 218,170 230,570 Prepaid expenses and other current assets 11,525 10,484 Total current assets 299,925 308,793 Long-term marketable securities 73,982 142,164 Property and equipment, net 14,037 16,321 Operating lease assets 30,081 32,218 Restricted cash 408 408 Other assets 1,968 2,622 Total assets $ 420,401 $ 502,526 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,029 $ 468 Accrued expenses and other current liabilities 20,798 26,308 Operating lease liabilities 4,885 4,619 Total current liabilities 28,712 31,395 Operating lease liabilities, net of current portion 43,408 47,270 Other liabilities 395 362 Total liabilities 72,515 79,027 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.0001 par value; 80,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value; 800,000,000 shares authorized at September 30, 2025 and December 31, 2024; 283,711,805 and 283,218,344 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 28 28 Additional paid-in capital 1,210,326 1,190,729 Accumulated other comprehensive income 649 405 Accumulated deficit ( 863,117 ) ( 767,663 ) Total stockholders' equity 347,886 423,499 Total liabilities and stockholders' equity $ 420,401 $ 502,526 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Erasca, Inc. Conde

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing